Healing Hearts - Saving Lives

The only transcatheter solution that combines repair and replacement for the Mitral valve in one procedure

  • Facebook
  • Twitter
  • YouTube
  • Pinterest
  • Tumblr Social Icon
  • Instagram
 

The

Opportunity

Globally there are more than 15 million Mitral Regurgitation (MR) patients;

4.5 million are suffering from severe MR

The treatments currently available for severe MR patients with heart failure are limited. Surgical repair and replacement are not possible for 98% of patients

Mortality and morbidity are high among untreated patients with mortality at 1-year up to 57%

 

The

Solution

VALFIX has developed an innovative transcatheter system to treat patients suffering from severe Mitral Regurgitation and Heart-Failure.
The unique and innovative multi-wire technology enables transcatheter Mitral valve repair and replacement in one procedure. 
VALFIX offers a true transcatheter complete ring annuloplasty procedure which is considered first-line therapy and the gold standard in Mitral surgery.
 

© 2020 by VALFIX Medical Ltd.

VALFIX products are not available for sale or commercial distribution.